Finally, we demonstrated the sensitivity of BCR-ABL-positive ALL to ABT-737 in a real-time in vivo validation assay using patient-derived primary ALL cells transduced with luciferase. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.